Grail (NASDAQ:GRAL - Get Free Report) is projected to post its quarterly earnings results before the market opens on Tuesday, February 11th. Analysts expect Grail to post earnings of ($4.41) per share for the quarter.
Grail (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($3.94) earnings per share (EPS) for the quarter. The company had revenue of $28.65 million during the quarter. On average, analysts expect Grail to post $-65 EPS for the current fiscal year and $-15 EPS for the next fiscal year.
Grail Price Performance
NASDAQ GRAL traded down $0.78 on Friday, reaching $32.21. The stock had a trading volume of 739,852 shares, compared to its average volume of 1,110,670. The business's 50-day moving average price is $21.43 and its 200 day moving average price is $17.04. Grail has a 12-month low of $12.33 and a 12-month high of $35.67.
Analyst Upgrades and Downgrades
GRAL has been the subject of a number of recent research reports. Morgan Stanley started coverage on shares of Grail in a research note on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 price target for the company. Guggenheim initiated coverage on Grail in a report on Thursday, October 17th. They set a "neutral" rating on the stock. Finally, Wolfe Research assumed coverage on Grail in a research report on Friday, November 15th. They issued a "peer perform" rating on the stock.
View Our Latest Stock Analysis on GRAL
Insider Buying and Selling
In other news, CFO Aaron Freidin sold 30,452 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $14.02, for a total transaction of $426,937.04. Following the completion of the transaction, the chief financial officer now directly owns 268,277 shares of the company's stock, valued at approximately $3,761,243.54. This represents a 10.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
About Grail
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Featured Articles
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
